Skip to main content
    M

    MacroGenics Inc (MGNX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.17
    -0.03 (-1.36%)

    Market Cap: $140.60M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MacroGenics Inc (MGNX) Earnings: Report Dates and Results

    Updated Nov 11, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    MacroGenics (MGNX) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, MacroGenics reported EPS of -$0.34, below the -$0.10 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    43%(17/40)
    Avg Surprise
    -24.29%

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.26
    Range-$0.48 - $0.33
    9 analysts
    Revenue Consensus
    $36.86M
    Range$16.86M - $76.65M
    8 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.51
    Range-$0.75 - -$0.30
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.38-33.6%
    60d ago-$0.510.0%
    30d ago-$0.510.0%
    7d ago-$0.510.0%
    Current-$0.51
    Revenue Consensus
    $8.25M
    Range$1.50M - $15.00M
    2 analysts

    Next Report

    MGNX has an expected report date of Mar 8, 2027.

    MGNX Earnings Call

    The latest MGNX earnings call transcript on file is labeled 2024Q2.

    Read the 2024Q2 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, MGNX beat 17 and missed 23. Revenue for the quarter ended Sep 30, 2026 was $18.67M, down 64.8% from $53.00M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.34-$0.10-$0.17 - -$0.08-240.00%Miss-225.9%20 up, 1 downNov 11, 2026$18.67M
    Jun 30, 2026-$0.27-$0.34-$0.70 - $1.71+20.59%BeatN/A40 up, 1 downAug 13, 2026$32.83M
    Mar 31, 2026-$0.58-$0.55-$0.73 - -$0.23-5.45%MissN/A40 up, 1 downMay 13, 2026$20.77M
    Dec 31, 2025-$0.22-$0.27N/A+18.40%BeatN/A20 up, 0 downMar 9, 2026$41.23M
    Sep 30, 2025$0.27-$0.44N/A+161.36%Beat-70.0%10 up, 1 downNov 12, 2025$53.00M
    Jun 30, 2025-$0.57$0.38$0.38 - $0.38-250.00%MissN/A10 up, 0 downAug 14, 2025$6.87M
    Mar 31, 2025-$0.65-$0.69-$0.69 - -$0.69+5.80%BeatN/A11 up, 0 downMay 13, 2025$13.19M
    Dec 31, 2024-$0.82-$0.59-$0.76 - -$0.42-38.64%MissN/A24 up, 1 downMar 20, 2025$19.35M
    Sep 30, 2024$0.90$0.60-$0.89 - $0.81+50.00%BeatN/A100 up, 0 downNov 5, 2024$110.71M
    Jun 30, 2024-$0.89-$0.59-$0.85 - $0.13-50.85%MissN/A111 up, 1 downAug 6, 2024$10.80M
    Mar 31, 2024-$0.84-$0.64-$0.77 - -$0.55-31.25%MissN/A111 up, 0 downMay 9, 2024$9.10M
    Dec 31, 2023-$0.75-$0.15-$0.37 - $0.38-400.00%Miss-457.1%100 up, 1 downMar 7, 2024$10.72M
    Sep 30, 2023-$0.52-$0.35-$0.80 - $0.29-48.57%MissN/A100 up, 1 downNov 6, 2023$10.40M
    Jun 30, 2023-$0.70-$0.50-$0.82 - -$0.18-40.00%MissN/A90 up, 1 downAug 9, 2023$13.14M
    Mar 31, 2023-$0.61$0.35-$0.82 - $1.44-274.29%MissN/A100 up, 0 downMay 9, 2023$24.50M
    Dec 31, 2022$0.21$0.10-$0.89 - $1.26+110.00%BeatN/A110 up, 2 downMar 15, 2023$73.10M
    Sep 30, 2022-$0.40-$0.36-$0.91 - $0.17-11.11%MissN/A110 up, 1 downNov 3, 2022$41.73M
    Jun 30, 2022-$0.67-$0.97-$1.09 - -$0.61+30.93%BeatN/A111 up, 0 downAug 8, 2022$26.01M
    Mar 31, 2022-$1.08-$0.85-$1.03 - -$0.68-27.06%MissN/A101 up, 0 downMay 3, 2022$11.10M
    Dec 31, 2021-$0.95-$0.81-$1.00 - -$0.71-17.28%MissN/A110 up, 0 downFeb 24, 2022$14.15M
    Sep 30, 2021-$0.86-$0.71-$0.90 - -$0.14-21.13%MissN/A90 up, 0 downNov 2, 2021$15.66M
    Jun 30, 2021-$0.66-$0.41-$1.03 - $1.45-60.98%MissN/A10N/AJul 29, 2021$30.76M
    Mar 31, 2021-$0.90-$0.63-$0.88 - -$0.16-42.86%MissN/A10N/AApr 29, 2021$16.88M
    Dec 31, 2020-$0.04-$0.60-$1.05 - -$0.25+93.33%BeatN/A10N/AFeb 25, 2021$52.69M
    Sep 30, 2020-$0.66-$1.02-$1.10 - -$0.72+35.29%BeatN/A10N/ANov 4, 2020$18.25M
    Jun 30, 2020-$0.94-$1.00-$1.12 - -$0.59+6.00%BeatN/A10N/AJul 30, 2020$20.26M
    Mar 31, 2020-$0.91-$1.02-$1.17 - -$0.80+10.78%BeatN/A11N/AMay 5, 2020$13.68M
    Dec 31, 2019-$0.62-$1.16-$1.42 - $0.22+46.55%BeatN/A12N/AFeb 25, 2020$25.19M
    Sep 30, 2019-$0.91-$1.11-$1.29 - -$0.30+18.02%BeatN/A11N/ANov 6, 2019$18.74M
    Jun 30, 2019-$1.05-$1.07-$1.33 - -$0.38+1.87%BeatN/A12N/AJul 31, 2019$10.59M
    Mar 31, 2019-$0.99-$0.87-$1.27 - -$0.37-13.79%MissN/A13N/AMay 1, 2019$9.66M
    Dec 31, 2018-$1.06-$1.02-$1.38 - -$0.60-3.92%Miss-135.8%11N/AFeb 26, 2019$15.79M
    Sep 30, 2018-$0.81-$1.30-$1.48 - -$1.05+37.69%BeatN/A11N/ANov 7, 2018$20.80M
    Jun 30, 2018-$1.03-$1.21-$1.36 - -$0.94+14.88%BeatN/A10N/AAug 7, 2018$18.83M
    Mar 31, 2018-$1.34-$1.10-$1.26 - -$0.86-21.82%MissN/A11N/AMay 7, 2018$4.70M
    Dec 31, 2017$2.96$2.21-$1.14 - $2.99+33.94%BeatN/A10N/AFeb 27, 2018$152.36M
    Sep 30, 2017-$1.28-$1.04-$1.21 - -$0.86-23.08%MissN/A10N/ANov 8, 2017$1.66M
    Jun 30, 2017-$1.14-$1.00-$1.17 - $1.01-14.00%Miss-201.8%11N/AAug 2, 2017$1.67M
    Mar 31, 2017-$1.08-$0.91N/A-18.68%MissN/AN/AN/AMay 3, 2017$2.06M
    Dec 31, 2016-$1.00-$0.89N/A-12.36%MissN/AN/AN/AFeb 28, 2017$5.11M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.17, after -$1.65 the year before. It was -$1.73 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.17N/A
    Dec 31, 2024-$1.65N/A
    Dec 31, 2023-$2.58N/A
    Dec 31, 2022-$1.94N/A
    Dec 31, 2021-$3.37N/A
    Dec 31, 2020-$2.55N/A
    Dec 31, 2019-$3.57N/A
    Dec 31, 2018-$4.24N/A
    Dec 31, 2017-$0.54N/A
    Dec 31, 2016-$1.73N/A

    Earnings Calls

    The only earnings call listed below, 2024Q2 for the period ended Jun 30, 2024, runs about 5,400 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q2Jun 30, 20245,39513

    2024Q2 Earnings Call

    Opening remarks

    James Karrels CFO Thank you, operator. Good afternoon, and welcome to MacroGenics' conference call to discuss our third quarter 2024 financial and operational results. For anyone who has not had the chance to review these results, we issued a press release this afternoon outlining today's announcements. This release is available under the Investors tab on our website at macrogenics.com. You may also listen to this conference call via webcast on our website, where it will be archived for 30 days beginning approximately two hours after the call is completed. I would like to alert listeners that today's discussion will include statements about the company's future expectations, plans and prospects that constitute forward-looking statements for purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual, quarterly and current reports filed with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change, except to the extent required by applicable law. And now, I'd like to turn the call over to Dr. Scott Koenig, President and Chief Executive Officer of MacroGenics.

    Scott Koenig CEO Thank you, Jim. I'd like to welcome everyone participating via conference call and webcast today. I will provide key updates on our clinical programs this afternoon. But before I do so, let me first turn the call back to Jim, who will review our financial results.

    James Karrels CFO Thank you, Scott. This afternoon, MacroGenics reported financial results for the quarter ended September 30, 2024, which highlight our financial position. As described in our release this afternoon, MacroGenics total revenue was $110.7 million for the quarter ended September 30, 2024, compared to total revenue of $10.4 million for the quarter ended September 30, 2023. The increase was primarily due to $100 million in milestones received from Incyte in August related to retifanlimab. Our research and development expenses were $40.5 million for the quarter ended September 30, 2024 compared to $30.1 million for the quarter ended September 30, 2023. The increase was primarily due to increased research and development costs related to the company's preclinical ADC pipeline, vobra duo and the TAMARACK clinical trial. Our selling, general and administrative expenses were $14.1 million for the quarter ended September 30, 2024 compared to $12.4 million for the quarter ended September 30, 2023.

    Frequently Asked Questions About MGNX

    When is MacroGenics's next earnings date?

    MacroGenics's next earnings report is expected for Mar 8, 2027.

    Did MGNX beat earnings estimates last quarter?

    No. MacroGenics reported EPS of -$0.34 for the quarter ended Sep 30, 2026, below the -$0.10 estimate by 240.00%.

    What EPS do analysts expect from MGNX next quarter?

    The consensus EPS estimate for MacroGenics for the quarter ending Dec 31, 2026 is -$0.26 from 9 analysts, with estimates from -$0.48 to $0.33.

    How often does MGNX beat earnings estimates?

    MacroGenics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -40.99%.